CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
A phase 2 trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells in mantle cell lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.
Overview
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT04718883 by Shanghai Ming Ju Biotechnology Co., Ltd., with 59 participants enrolled, started 2021-01-13 and due to reach its primary completion in 2023-10-25. Interventions recorded: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells.
Similar pages
not linked directly; found by shared links- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Mantle cell lymphoma and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Mantle cell lymphoma and the tag pipeline.
- TrialStudy of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Shares Mantle cell lymphoma and the tag pipeline.
- TreatmentCTX112
Shares Mantle cell lymphoma and the tag pipeline.
- TrialStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Shares Mantle cell lymphoma and the tag pipeline.
- TreatmentICP-248
Shares Mantle cell lymphoma and the tag pipeline.
- TreatmentZamtocabtagene autoleucel
Shares Mantle cell lymphoma and the tag pipeline.
- TreatmentRocbrutinib
Shares Mantle cell lymphoma and the tag pipeline.